July 09, 2007 11:30 ET

MEDRAD Awarded Agreement by University Health Network / Mount Sinai Hospital / Women's College Hospital - Toronto

Landmark Canadian Healthcare System Partners With MEDRAD for Innovative Imaging and Patient Care Products

WARRENDALE, PA--(Marketwire - July 9, 2007) - The Joint Department of Medical Imaging of the University Health Network (UHN) / Mount Sinai Hospital (MSH) / Women's College Hospital (WCH), based in Toronto, Ontario, Canada, has selected Pittsburgh-based MEDRAD, INC. as its contract supplier partner for Vascular Injection Systems used in computed tomography (CT), magnetic resonance (MR), and cardiovascular imaging procedures and for MR Patient Monitoring Systems throughout all of its respective member facilities.

Through this product standardization agreement, the Joint Department of Medical Imaging can access a broad range of MEDRAD products at industry-leading values to enhance cardiac imaging, patient care services, and more. Among the innovative products included in the agreement are the Stellant® Dual CT Injection System, which enables simultaneous injection of contrast and saline for improved cardiac CT Imaging, and the Veris® MR Patient Monitor that allows clinicians to monitor patient vital signs during MR imaging. Together with the revolutionary Certo™ MR Wireless Network, Veris can promote more efficient and attentive patient care by permitting continuous, remote monitoring of multiple patients in preparation rooms and post-procedure recovery areas.

Scott Jarrett, senior director at the Joint Department of Medical Imaging, said, "This agreement with MEDRAD lets us standardize products across our facilities with obvious benefits for patient safety and quality. We're also happy to have a partner for wireless networking that will keep mission critical medical devices operational."

"Strengthening our relationships in Canada and in the more than 85 countries in which we have a presence solidifies our position as a trusted partner and market leader," said John Tedeschi, senior vice president, MEDRAD Global Field Organization. "We're honored that the Joint Department of Medical Imaging trusts MEDRAD with its members' most important priority -- the care of their patients."

MEDRAD's Country Manager - Canada, Mark Chelberg, added, "To have the chance to partner with global clinical leaders is exciting. With the new partnership, we can help improve patient care and diagnostic capability though the utilization of new technology in Canada."

MEDRAD will also supply power injection systems for MR, the Spectris Solaris® EP MR Injection System, and for cardiovascular applications, the MEDRAD Avanta® Fluid Management Injection System. Along with the Vanguard Dx® Angiographic Catheter line, MEDRAD Avanta is a system that can be used to manage contrast and saline injection for virtually all cardiovascular procedures.

The University Health Network is a major landmark provider in Canada's healthcare system, providing care for more than 200 years through its three hospitals, Toronto General, Toronto Western, and Princess Margaret. Mount Sinai Hospital is a world-class healthcare facility discovering and delivering the best in patient care, teaching and research. Women's College Hospital has a rich history -- leading the way in providing care to women and their families for well over a century.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at

Bayer AG is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. The company's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Contact Information

  • For additional information contact:
    Mark Chelberg
    MEDRAD Country Manager - Canada
    412-767-2400 ext. 8210
    Email Contact

    Dan Dieter
    MEDRAD Marketing Services
    Email Contact